What are the major opportunities in the Sylvant (Siltuximab) market? What are the strategies for the Sylvant (Siltuximab) market?

For detailed insights on the major opportunities and strategies in the Sylvant (Siltuximab) market, Read More

How does the Sylvant (Siltuximab) market relate to the overall economy and other similar markets?

For detailed insights on Sylvant (Siltuximab)'s relation to the overall economy and other similar markets, Read More

What are the latest mergers and acquisitions in the Sylvant (Siltuximab) industry?

For detailed insights on the mergers and acquisitions in the Sylvant (Siltuximab) industry, Read More

What are the key dynamics influencing the Sylvant (Siltuximab) market growth? SWOT analysis of the Sylvant (Siltuximab) market.

For detailed insights on the key dynamics influencing the Sylvant (Siltuximab) market growth and SWOT analysis of the Sylvant (Siltuximab) industry, Read More

Global Sylvant Siltuximab Market Report 2025

Item added to cart!

Published : December 2025

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Sylvant (Siltuximab) Global Market Report 2025

Name: Sylvant (Siltuximab) Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Indication (Multicentric Castleman Disease (MCD), Human Immunodeficiency Virus (HIV)-Associated Multicentric Castleman Disease (MCD), Non-Hodgkin Lymphoma (NHL)), By Application (Injections, Vials, Lyophilized Powde, Solution For Infusion, Prefilled Syringes), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Home Care)

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Sylvant (Siltuximab) Market?

Sylvant (siltuximab) is a monoclonal antibody that targets and neutralizes interleukin-6 (IL-6), a cytokine involved in inflammation and immune responses. By inhibiting IL-6, it helps reduce inflammation and regulate immune activity, particularly in conditions such as multicentric castleman's disease (MCD). It is used to manage MCD symptoms, improve quality of life, and slow disease progression.

The main types of indication for sylvant (siltuximab) are multicentric castleman disease (MCD), human immunodeficiency virus (HIV)-associated multicentric castleman disease (MCD), and Non-Hodgkin Lymphoma (NHL). Multicentric castleman disease (MCD) is a rare immune disorder causing lymphoid tissue overgrowth, and Sylvant (Siltuximab) treats it by targeting specific proteins to reduce inflammation and improve outcomes. It is used for several applications, such as injections, vials, lyophilized powder, solutions for infusion, and prefilled syringes, and is used by various end users, including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and home care.

Sylvant (Siltuximab) Market Size and growth rate 2025 to 2029: Graph

What Is The Sylvant (Siltuximab) Market Size 2025 And Growth Rate?

The sylvant (siltuximab) market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increasing R&D activities for novel therapeutics drugs, rising prevalence of rare diseases, rising healthcare expenditure, awareness and patient advocacy, clinical trial success and data publication, increasing focus on biologic medicines.

What Is The Sylvant (Siltuximab) Market Growth Forecast?

The sylvant (siltuximab) market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising adoption of biologic therapies, shifting focus toward precision medicine, increasing prevalence of multicentric castleman disease (MCD), advances in immunology and oncology, favorable reimbursement policies. Major trends in the forecast period include growing demand for biologic therapies, expansion of indications and clinical research, advancement in for castleman disease patients, regulatory approvals and market access, increasing immunotherapy demand.

Book your 30 minutes free consultation with our research experts

How Is The Sylvant (Siltuximab) Market Segmented?

The sylvant (siltuximab) market covered in this report is segmented –

1) By Indication: Multicentric Castleman Disease (MCD); Human Immunodeficiency Virus (HIV)-Associated Multicentric Castleman Disease (MCD); Non-Hodgkin Lymphoma (NHL)

2) By Application: Injections; Vials; Lyophilized Powde; Solution For Infusion; Prefilled Syringes

3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Home Care

What Is Driving The Sylvant (Siltuximab) Market? Rising Prevalence Of Multicentric Castleman Disease (MCD) Driving Growth Of The Market

The increasing prevalence of multicentric castleman disease (MCD) is significantly driving the growth of the sylvant (siltuximab) market in the future. Multicentric castleman disease (MCD) is a rare condition involving the abnormal enlargement of lymph nodes and tissues, commonly linked to inflammation and immune system abnormalities. The rising cases of multicentric castleman disease (MCD) are attributed to factors such as improved diagnosis, greater awareness, and advancements in medical imaging. Sylvant (siltuximab) works by targeting and blocking interleukin-6 (IL-6), a cytokine that contributes to inflammation and disease progression in MCD. This inhibition helps reduce inflammation and control the abnormal growth of lymph nodes and tissues, offering an effective treatment for MCD patients. For instance, in June 2022, according to the National Organization for Rare Disorders, a US-based nonprofit organization, each year, approximately 4,300 to 5,200 new cases of castleman disease (CD) are diagnosed in the United States. Therefore, increasing prevalence of multicentric castleman disease (MCD) is driving the growth of the sylvant (siltuximab) market.

What Is Driving The Sylvant (Siltuximab) Market? Rising Demand For Precision Medicine Drives Growth In The Market

The shifting focus toward precision medicine is expected to propel the growth of the sylvant (siltuximab) market going forward. Precision medicine is a healthcare approach that customizes treatments based on a person's unique genetic makeup, environment, and lifestyle. The demand for precision medicine is rising due to advancements in genetic research, increasing prevalence of personalized healthcare, and growing adoption of targeted therapies. Sylvant (siltuximab) targets and inhibits interleukin-6 (IL-6), a cytokine involved in inflammation and disease progression. By specifically addressing elevated IL-6 levels in patients with multicentric castleman disease (MCD), it offers a more personalized and more effective treatment compared to standard therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the shifting focus toward precision medicine is driving the growth of the sylvant (siltuximab) market.

Who Are The Major Players In The Global Sylvant (Siltuximab) Market?

Major companies operating in the sylvant (siltuximab) market are Recordati Rare Diseases Inc.

What Are The Key Trends Of The Global Sylvant (Siltuximab) Market? Strategic Partnerships To Enhance Patient Outcomes And Address Unmet Clinical Needs

The key trend in the sylvant (siltuximab) market is focusing on developing a strategic partnership approach to improve patient outcomes in China, addressing the urgent clinical need for therapies in the country. Strategic partnerships involve collaborations between organizations to combine their strengths, resources, and expertise in order to achieve shared objectives and foster growth. For instance, EUSA Pharma, a UK-based pharmaceutical company, partnered with BeiGene, a China-based biotechnology company, and announced that the China National Medical Products Administration (NMPA) had accepted their Biologics License Application (BLA) for Sylvant (siltuximab for injection). This application seeks approval for the treatment of idiopathic multicentric Castleman disease (iMCD), a rare and serious condition that affects the lymph nodes. Siltuximab is already approved in more than 40 countries, and its acceptance for review by the NMPA represents a significant milestone in expanding treatment options for patients suffering from this debilitating disease in China.

Need data on a specific region in this market?

Request Regional Data

Regional Analysis For The Global Sylvant (Siltuximab) Market

North America was the largest region in the sylvant (siltuximab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sylvant (siltuximab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sylvant (siltuximab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sylvant (Siltuximab) Market?

The sylvant (siltuximab) market consists of sales of oral dosage forms, compounded solutions, and intravenous (IV) infusion bags. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Sylvant (Siltuximab) Industry?

The sylvant (siltuximab) market research report is one of a series of new reports from The Business Research Company that provides sylvant (siltuximab) market statistics, including the sylvant (siltuximab) industry global market size, regional shares, competitors with the sylvant (siltuximab) market share, detailed sylvant (siltuximab) market segments, market trends, and opportunities, and any further data you may need to thrive in the sylvant (siltuximab) industry. This sylvant (siltuximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abhilash Pyata

Sylvant Siltuximab Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	Included ?
Revenue Forecast In 2034	Included ?
Growth Rate	Included ?
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The sylvant (siltuximab) market covered in this report is segmented – 1) By Indication: Multicentric Castleman Disease (MCD); Human Immunodeficiency Virus (HIV)-Associated Multicentric Castleman Disease (MCD); Non-Hodgkin Lymphoma (NHL) 2) By Application: Injections; Vials; Lyophilized Powde; Solution For Infusion; Prefilled Syringes 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Home Care
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Recordati Rare Diseases Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Sylvant (Siltuximab) Market Characteristics

3. Sylvant (Siltuximab) Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Sylvant (Siltuximab) Market Trends And Strategies

5. Sylvant (Siltuximab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

6. Global Sylvant (Siltuximab) Growth Analysis And Strategic Analysis Framework

6.1. Global Sylvant (Siltuximab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Sylvant (Siltuximab) Market Growth Rate Analysis

6.4. Global Sylvant (Siltuximab) Historic Market Size and Growth, 2019 - 2024, Value ($ Million)

6.5. Global Sylvant (Siltuximab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)

6.6. Global Sylvant (Siltuximab) Total Addressable Market (TAM)

7. Global Sylvant (Siltuximab) Pricing Analysis & Forecasts

8. Sylvant (Siltuximab) Market Segmentation

8.1. Global Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Multicentric Castleman Disease (MCD)

Human Immunodeficiency Virus (HIV)-Associated Multicentric Castleman Disease (MCD)

Non-Hodgkin Lymphoma (NHL)

8.2. Global Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Injections

Vials

Lyophilized Powde

Solution For Infusion

Prefilled Syringes

8.3. Global Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Hospitals

Specialty Clinics

Ambulatory Surgical Centers (ASCs)

Home Care

9. Global Sylvant (Siltuximab) Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Sylvant (Siltuximab) Market Regional And Country Analysis

10.1. Global Sylvant (Siltuximab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

10.2. Global Sylvant (Siltuximab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Sylvant (Siltuximab) Market

11.1. Asia-Pacific Sylvant (Siltuximab) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.3. Asia-Pacific Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.4. Asia-Pacific Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Sylvant (Siltuximab) Market

12.1. China Sylvant (Siltuximab) Market Overview

12.2. China Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.3. China Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.4. China Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Sylvant (Siltuximab) Market

13.1. India Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.2. India Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.3. India Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Sylvant (Siltuximab) Market

14.1. Japan Sylvant (Siltuximab) Market Overview

14.2. Japan Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.3. Japan Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.4. Japan Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Sylvant (Siltuximab) Market

15.1. Australia Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.2. Australia Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.3. Australia Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Sylvant (Siltuximab) Market

16.1. South Korea Sylvant (Siltuximab) Market Overview

16.2. South Korea Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.3. South Korea Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.4. South Korea Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Sylvant (Siltuximab) Market

17.1. Western Europe Sylvant (Siltuximab) Market Overview

17.2. Western Europe Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.3. Western Europe Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.4. Western Europe Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Sylvant (Siltuximab) Market

18.1. UK Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.2. UK Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.3. UK Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Sylvant (Siltuximab) Market

19.1. Germany Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.2. Germany Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.3. Germany Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Sylvant (Siltuximab) Market

20.1. France Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.2. France Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.3. France Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Sylvant (Siltuximab) Market

21.1. Eastern Europe Sylvant (Siltuximab) Market Overview

21.2. Eastern Europe Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.3. Eastern Europe Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.4. Eastern Europe Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Sylvant (Siltuximab) Market

22.1. North America Sylvant (Siltuximab) Market Overview

22.2. North America Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.3. North America Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.4. North America Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Sylvant (Siltuximab) Market

23.1. USA Sylvant (Siltuximab) Market Overview

23.2. USA Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.3. USA Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.4. USA Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Sylvant (Siltuximab) Market

24.1. Canada Sylvant (Siltuximab) Market Overview

24.2. Canada Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.3. Canada Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.4. Canada Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Sylvant (Siltuximab) Market

25.1. South America Sylvant (Siltuximab) Market Overview

25.2. South America Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.3. South America Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.4. South America Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Sylvant (Siltuximab) Market

26.1. Middle East Sylvant (Siltuximab) Market Overview

26.2. Middle East Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.3. Middle East Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.4. Middle East Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Sylvant (Siltuximab) Market

27.1. Africa Sylvant (Siltuximab) Market Overview

27.2. Africa Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.3. Africa Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.4. Africa Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Sylvant (Siltuximab) Market Competitive Landscape And Company Profiles

28.1. Sylvant (Siltuximab) Market Competitive Landscape

28.2. Sylvant (Siltuximab) Market Company Profiles

28.2.1. Recordati Rare Diseases Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Sylvant (Siltuximab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Sylvant (Siltuximab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Sylvant (Siltuximab) Market

32. Recent Developments In The Sylvant (Siltuximab) Market

33. Sylvant (Siltuximab) Market High Potential Countries, Segments and Strategies

33.1 Sylvant (Siltuximab) Market In 2029 - Countries Offering Most New Opportunities

33.2 Sylvant (Siltuximab) Market In 2029 - Segments Offering Most New Opportunities

33.3 Sylvant (Siltuximab) Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Million

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Table 3: Global Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 4: Global Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 5: Global Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 6: Global Sylvant (Siltuximab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 7: Global Sylvant (Siltuximab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 8: Asia-Pacific, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 9: Asia-Pacific, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 10: Asia-Pacific, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 11: China, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 12: China, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 13: China, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 14: India, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 15: India, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 16: India, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 17: Japan, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 18: Japan, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 19: Japan, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 20: Australia, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 21: Australia, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 22: Australia, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 23: South Korea, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 24: South Korea, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 25: South Korea, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 26: Western Europe, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 27: Western Europe, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 28: Western Europe, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 29: UK, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 30: UK, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 31: UK, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 32: Germany, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 33: Germany, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 34: Germany, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 35: France, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 36: France, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 37: France, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 38: Eastern Europe, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 39: Eastern Europe, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 40: Eastern Europe, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 41: North America, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 42: North America, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 43: North America, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 44: USA, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 45: USA, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 46: USA, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 47: Canada, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 48: Canada, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 49: Canada, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 50: South America, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 51: South America, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 52: South America, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 53: Middle East, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 54: Middle East, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 55: Middle East, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 56: Africa, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 57: Africa, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 58: Africa, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 59: Recordati Rare Diseases Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Million

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Figure 3: Global Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 4: Global Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 5: Global Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 6: Global Sylvant (Siltuximab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 7: Global Sylvant (Siltuximab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 8: Asia-Pacific, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 9: Asia-Pacific, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 10: Asia-Pacific, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 11: China, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 12: China, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 13: China, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 14: India, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 15: India, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 16: India, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 17: Japan, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 18: Japan, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 19: Japan, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 20: Australia, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 21: Australia, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 22: Australia, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 23: South Korea, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 24: South Korea, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 25: South Korea, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 26: Western Europe, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 27: Western Europe, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 28: Western Europe, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 29: UK, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 30: UK, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 31: UK, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 32: Germany, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 33: Germany, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 34: Germany, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 35: France, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 36: France, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 37: France, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 38: Eastern Europe, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 39: Eastern Europe, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 40: Eastern Europe, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 41: North America, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 42: North America, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 43: North America, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 44: USA, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 45: USA, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 46: USA, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 47: Canada, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 48: Canada, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 49: Canada, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 50: South America, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 51: South America, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 52: South America, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 53: Middle East, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 54: Middle East, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 55: Middle East, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 56: Africa, Sylvant (Siltuximab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 57: Africa, Sylvant (Siltuximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 58: Africa, Sylvant (Siltuximab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 59: Recordati Rare Diseases Inc. Financial Performance

2025 Over-The-Counter (OTC) Diet Products Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

G-CSF (Granulocyte Colony Stimulating Factors) Market 2021 - By Type (Pegfilgrastim, Filgrastim, Lenograstim), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders), And By Region, Opportunities An...

Anemia And Other Blood Disorder Drugs Global Market Report 2025 – By Type (Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia), By Route of Administration (Oral, Injectable), By Di...

Antibody Drug Conjugates Global Market Report 2025 – By Type (Monoclonal Antibodies, Linker, Drug/Toxin, Other Types), By Product (Adcertis, Kadcyla, Other Products), By Technology (Immunogen Technology, Seattle Genetics...

Antibody Contract Manufacturing Global Market Report 2025 – By Product (Monoclonal Antibodies, Polyclonal Antibodies, Other Products), By Source (Mammalian, Microbial, Scale Of Operation (Preclinical, Clinical, Commercia...

Next-Generation Antibody Therapeutics Global Market Report 2025 – By Types Of Antibodies (Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types), By Therapeutic Area ...

Antibody Discovery Global Market Report 2025 – By Methods (Phage Display, Hybridoma, Other Methods), By Antibody Type (Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody), By End Users (Pharmaceutical...

Cell Therapy Global Market Report 2025 – By Technique (Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy), By Therapy Type (Allogeneic Therapies, Autologous ...

Frequently Asked Questions

What is the definition of the Sylvant (Siltuximab) market?

How will the Sylvant (Siltuximab) market drivers and restraints affect the market dynamics? What forces will shape the Sylvant (Siltuximab) industry going forward?

The Sylvant (Siltuximab) market major growth driver - Rising Prevalence Of Multicentric Castleman Disease (MCD) Driving Growth Of The Market. For further insights on the Sylvant (Siltuximab) market, request a sample here

What is the forecast market size or the forecast market value of the Sylvant (Siltuximab) market?

The Sylvant (Siltuximab) market size has grown strongly in recent years. The sylvant (siltuximab) market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increasing R&D activities for novel therapeutics drugs, rising prevalence of rare diseases, rising healthcare expenditure, awareness and patient advocacy, clinical trial success and data publication, increasing focus on biologic medicines. The sylvant (siltuximab) market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising adoption of biologic therapies, shifting focus toward precision medicine, increasing prevalence of multicentric castleman disease (MCD), advances in immunology and oncology, favorable reimbursement policies. Major trends in the forecast period include growing demand for biologic therapies, expansion of indications and clinical research, advancement in for castleman disease patients, regulatory approvals and market access, increasing immunotherapy demand. For further insights on the Sylvant (Siltuximab) market, request a sample here

How is the Sylvant (Siltuximab) market segmented?

The sylvant (siltuximab) market covered in this report is segmented –
1) By Indication: Multicentric Castleman Disease (MCD); Human Immunodeficiency Virus (HIV)-Associated Multicentric Castleman Disease (MCD); Non-Hodgkin Lymphoma (NHL)
2) By Application: Injections; Vials; Lyophilized Powde; Solution For Infusion; Prefilled Syringes
3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Home Care For further insights on the Sylvant (Siltuximab) market, request a sample here

Which region has the largest share of the Sylvant (Siltuximab) market? What are the other regions covered in the report?

Who are the major players in the Sylvant (Siltuximab) market?

Major companies operating in the sylvant (siltuximab) market are Recordati Rare Diseases Inc. . For further insights on the Sylvant (Siltuximab) market, request a sample here.

What are the key trends in the Sylvant (Siltuximab) market?

Major trends in the Sylvant (Siltuximab) market include Strategic Partnerships To Enhance Patient Outcomes And Address Unmet Clinical Needs. For further insights on the Sylvant (Siltuximab) market, request a sample here.